Funding for this research was provided by:
Leon Levy Foundation (n/a)
Received: 9 January 2022
Accepted: 7 June 2022
First Online: 4 July 2022
: V.V.S. and R.H. have an equity interest in Minotaur Therapeutics which has a license to the MNT-002 molecule. The authors declare no other competing interests.